Forvis Mazars Wealth Advisors LLC Sells 955 Shares of Johnson & Johnson (NYSE:JNJ)

Forvis Mazars Wealth Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 2.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 42,637 shares of the company’s stock after selling 955 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $6,166,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Howard Capital Management Inc. raised its stake in Johnson & Johnson by 5.8% in the 4th quarter. Howard Capital Management Inc. now owns 18,879 shares of the company’s stock valued at $2,730,000 after acquiring an additional 1,029 shares during the period. Integral Investment Advisors Inc. increased its position in Johnson & Johnson by 1.7% during the 4th quarter. Integral Investment Advisors Inc. now owns 16,822 shares of the company’s stock worth $2,433,000 after buying an additional 288 shares during the period. Tradewinds Capital Management LLC increased its position in Johnson & Johnson by 311.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 12,524 shares of the company’s stock worth $1,811,000 after buying an additional 9,481 shares during the period. Marshall Investment Management LLC bought a new position in Johnson & Johnson during the 4th quarter worth $1,171,000. Finally, ST. Nicholas Private Asset Management Inc. bought a new position in Johnson & Johnson during the 4th quarter worth $1,576,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $166.13 on Wednesday. The stock’s 50-day simple moving average is $149.72 and its 200 day simple moving average is $155.92. The firm has a market capitalization of $399.98 billion, a PE ratio of 24.98, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analyst Weigh In

Several research firms have weighed in on JNJ. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Stifel Nicolaus lowered their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Guggenheim increased their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Morgan Stanley decreased their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.